D-Index & Metrics Best Publications

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 80 Citations 19,197 295 World Ranking 9813 National Ranking 5307

Overview

What is he best known for?

The fields of study he is best known for:

  • Internal medicine
  • Psychiatry
  • Major depressive disorder

Edward V. Nunes mainly investigates Psychiatry, Substance abuse, Placebo, Internal medicine and Randomized controlled trial. His Psychiatry study incorporates themes from Clinical trial and Clinical psychology. Edward V. Nunes has included themes like Alcohol dependence, Contingency management, Public health, Mental health and Cognitive therapy in his Substance abuse study.

His research in Placebo intersects with topics in Imipramine, Anesthesia, Pharmacotherapy and Discontinuation. In his study, Clinical Global Impression is inextricably linked to Placebo-controlled study, which falls within the broad field of Internal medicine. As a member of one scientific family, Edward V. Nunes mostly works in the field of Randomized controlled trial, focusing on Attention deficit hyperactivity disorder and, on occasion, Bupropion and Cognitive behavioral therapy.

His most cited work include:

  • Treatment of depression in patients with alcohol or other drug dependence: a meta-analysis. (434 citations)
  • Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial (355 citations)
  • Cognitive deficits predict low treatment retention in cocaine dependent patients (314 citations)

What are the main themes of his work throughout his whole career to date?

His primary scientific interests are in Psychiatry, Clinical psychology, Substance abuse, Randomized controlled trial and Internal medicine. His work carried out in the field of Psychiatry brings together such families of science as Placebo and Clinical trial. His Clinical psychology research is multidisciplinary, relying on both Psychological intervention, Psychosocial, Cognition, Anxiety and Comorbidity.

His Substance abuse study combines topics from a wide range of disciplines, such as Methadone, Epidemiology, Public health, Mental health and Cognitive therapy. The concepts of his Randomized controlled trial study are interwoven with issues in Buprenorphine, Opioid use disorder, Intervention and Naltrexone. The Internal medicine study combines topics in areas such as Relapse prevention and Drug.

He most often published in these fields:

  • Psychiatry (56.35%)
  • Clinical psychology (29.01%)
  • Substance abuse (28.73%)

What were the highlights of his more recent work (between 2018-2021)?

  • Opioid use disorder (14.92%)
  • Buprenorphine (11.60%)
  • Randomized controlled trial (20.99%)

In recent papers he was focusing on the following fields of study:

Edward V. Nunes spends much of his time researching Opioid use disorder, Buprenorphine, Randomized controlled trial, Naltrexone and Opioid. Edward V. Nunes interconnects Opioid overdose, Psychiatry and Buprenorphine/naloxone in the investigation of issues within Opioid use disorder. Psychiatry and Extramural are two areas of study in which Edward V. Nunes engages in interdisciplinary research.

His Buprenorphine research includes themes of Methadone, Psychological intervention, Logistic regression, Intensive care medicine and Substance abuse. His study in Substance abuse is interdisciplinary in nature, drawing from both Discontinuation and Substance use. The study incorporates disciplines such as Placebo and Abstinence in addition to Internal medicine.

Between 2018 and 2021, his most popular works were:

  • Development of a Cascade of Care for responding to the opioid epidemic (63 citations)
  • Development of a Cascade of Care for responding to the opioid epidemic (63 citations)
  • A Randomized Trial Comparing Extended-Release Injectable Suspension and Oral Naltrexone, Both Combined With Behavioral Therapy, for the Treatment of Opioid Use Disorder. (31 citations)

In his most recent research, the most cited papers focused on:

  • Internal medicine
  • Psychiatry
  • Major depressive disorder

His primary areas of investigation include Opioid use disorder, Buprenorphine, Methadone, Naltrexone and Randomized controlled trial. Opioid use disorder is a primary field of his research addressed under Internal medicine. His Internal medicine study combines topics in areas such as Crossover study and Placebo-controlled study.

As a part of the same scientific family, Edward V. Nunes mostly works in the field of Methadone, focusing on Psychological intervention and, on occasion, Psychosocial, Mood, Clinical psychology and Craving. His Naltrexone research is under the purview of Opioid. His biological study spans a wide range of topics, including Psychotherapist, Mindfulness, Anesthesia and Addiction.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Treatment of depression in patients with alcohol or other drug dependence: a meta-analysis.

Edward V. Nunes;Frances R. Levin.
JAMA (2004)

672 Citations

Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial

Evgeny Krupitsky;Edward V Nunes;Walter Ling;Ari Illeperuma.
The Lancet (2011)

531 Citations

Cognitive deficits predict low treatment retention in cocaine dependent patients

Efrat Aharonovich;Deborah S. Hasin;Adam C. Brooks;Xinhua Liu.
Drug and Alcohol Dependence (2006)

473 Citations

Effects of major depression on remission and relapse of substance dependence.

Deborah Hasin;Xinhua Liu;Edward Nunes;Steven McCloud.
Archives of General Psychiatry (2002)

447 Citations

Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial.

Joshua D Lee;Edward V Nunes;Patricia Novo;Ken Bachrach.
The Lancet (2017)

402 Citations

Rates of Psychiatric Comorbidity Among U.S. Residents with Lifetime Cannabis Dependence

Vito Agosti;Edward Nunes;Frances Levin.
American Journal of Drug and Alcohol Abuse (2002)

364 Citations

Cognitive impairment, retention and abstinence among cocaine abusers in cognitive-behavioral treatment

Efrat Aharonovich;Edward Nunes;Deborah Hasin.
Drug and Alcohol Dependence (2003)

363 Citations

Divalproex treatment for youth with explosive temper and mood lability: a double-blind, placebo-controlled crossover design.

Stephen J. Donovan;Jonathan W. Stewart;Edward V. Nunes;Frederic M. Quitkin.
American Journal of Psychiatry (2000)

352 Citations

Do treatment improvements in PTSD severity affect substance use outcomes? A secondary analysis from a randomized clinical trial in NIDA's Clinical Trials Network.

Denise A. Hien;Huiping Jiang;Aimee N.C. Campbell;Mei-Chen Hu.
American Journal of Psychiatry (2010)

323 Citations

Multisite randomized trial of behavioral interventions for women with co-occurring PTSD and substance use disorders.

Denise A. Hien;Elizabeth A. Wells;Huiping Jiang;Lourdes Suarez-Morales.
Journal of Consulting and Clinical Psychology (2009)

315 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Edward V. Nunes

Deborah S. Hasin

Deborah S. Hasin

Columbia University

Publications: 95

Kathleen T. Brady

Kathleen T. Brady

Medical University of South Carolina

Publications: 68

Roger D. Weiss

Roger D. Weiss

Harvard University

Publications: 64

Nora D. Volkow

Nora D. Volkow

National Institute on Drug Abuse

Publications: 57

Kathleen M. Carroll

Kathleen M. Carroll

Yale University

Publications: 57

Denise A. Hien

Denise A. Hien

Rutgers, The State University of New Jersey

Publications: 57

Frances R. Levin

Frances R. Levin

Columbia University

Publications: 53

Michael D. Stein

Michael D. Stein

Boston University

Publications: 49

Thomas R. Kosten

Thomas R. Kosten

Baylor College of Medicine

Publications: 47

Bridget F. Grant

Bridget F. Grant

National Institutes of Health

Publications: 44

Michael J. Zvolensky

Michael J. Zvolensky

The University of Texas MD Anderson Cancer Center

Publications: 44

Michael E. Thase

Michael E. Thase

University of Pennsylvania

Publications: 42

George E. Woody

George E. Woody

University of Pennsylvania

Publications: 41

Shelly F. Greenfield

Shelly F. Greenfield

Harvard University

Publications: 40

Marc N. Potenza

Marc N. Potenza

Yale University

Publications: 38

Madhukar H. Trivedi

Madhukar H. Trivedi

The University of Texas Southwestern Medical Center

Publications: 36

Trending Scientists

Philip Molyneux

Philip Molyneux

Bangor University

Bracha Shapira

Bracha Shapira

Ben-Gurion University of the Negev

Scott Bair

Scott Bair

Georgia Institute of Technology

H. T. Davis

H. T. Davis

University of Minnesota

Gordon F. Newell

Gordon F. Newell

University of California, Berkeley

Muhammad Iqbal Bhanger

Muhammad Iqbal Bhanger

National Centre of Excellence in Analytical Chemistry

Guohua Chen

Guohua Chen

Hong Kong Polytechnic University

László Virág

László Virág

University of Debrecen

Jacques Guillot

Jacques Guillot

École nationale vétérinaire d'Alfort

Norman J. Pieniazek

Norman J. Pieniazek

Centers for Disease Control and Prevention

Johan C. Winterwerp

Johan C. Winterwerp

Delft University of Technology

Vincent O'Flaherty

Vincent O'Flaherty

National University of Ireland, Galway

Martin T. Auer

Martin T. Auer

Michigan Technological University

Kathryn A. Davis

Kathryn A. Davis

University of Pennsylvania

Arne Ohlsson

Arne Ohlsson

University of Toronto

Andrew Heathcote

Andrew Heathcote

University of Tasmania

Something went wrong. Please try again later.